People stop taking NMN for a range of reasons: underwhelming results after weeks or months of use, concerns about cancer risk, the high ongoing cost, regulatory uncertainty, and doubts about product quality. While NMN has generated enormous interest as a longevity supplement, the gap between animal research and proven human benefits is wide enough that many users eventually decide it’s not worth continuing.
The Benefits Often Feel Underwhelming
The most common reason people quit NMN is simple: they don’t notice much happening. In a placebo-controlled trial of older men taking 250 mg of NMN daily for up to 12 weeks, researchers found only modest improvements in gait speed and grip strength in one hand, with no significant changes in body composition or cognitive function. NAD+ levels in the blood did rise, but that biochemical change didn’t translate into the dramatic energy boost or mental sharpness that supplement marketing often implies.
A separate multicenter trial tested doses of 300, 600, and 900 mg daily and found that blood NAD+ levels peaked at the 600 mg dose, with 900 mg offering no additional benefit. Physical performance improvements were real but modest. For people spending $50 to $150 per month on a supplement, “modest” can feel like “not enough.” Many users try NMN for three to six months, notice nothing obvious, and reasonably conclude the cost isn’t justified by their experience.
Cancer Risk Concerns
A growing worry among NMN users involves cancer. Because NMN raises NAD+ levels throughout the body, it fuels cellular energy in all cells, including ones that may be precancerous. Research presented through the American Association for Cancer Research found that mice given NMN developed more skin tumors after UV exposure than mice that didn’t receive the supplement. The NMN-supplemented tumors also showed higher rates of cell division and more aggressive genetic signatures, including markers associated with tumor spread.
In lab dishes, skin cancer cells exposed to NMN grew faster and migrated more readily. The researchers concluded that continuous NMN supplementation in conditions where someone is already predisposed to cancer “might enhance development and progression of skin cancer.” This is animal and cell research, not a completed human cancer trial, but for people with a personal or family history of cancer, the theoretical risk is enough to tip the scales toward stopping. NAD+ doesn’t distinguish between healthy cells and dangerous ones, and that lack of selectivity makes some users uncomfortable.
Product Quality Is Hard to Verify
NMN is notoriously difficult for consumers to evaluate. An analysis published in GeroScience tested multiple NMN supplements against their label claims and found significant discrepancies. Some products contained less NMN than advertised, likely because the active ingredient degrades over time. Others contained more than labeled, suggesting manufacturers deliberately overfill to compensate for expected breakdown. Either way, users can’t be confident they’re getting a consistent dose.
NMN is sensitive to heat, moisture, and light. Without rigorous third-party testing (which many brands skip or perform infrequently), a bottle sitting in a warehouse or on a store shelf may contain a fraction of the NMN it claims. For people who value precision in their health decisions, this uncertainty becomes a reason to stop.
The Regulatory Rollercoaster
NMN’s legal status in the United States has been a source of confusion and anxiety. In November 2022, the FDA declared that NMN was excluded from the dietary supplement definition, arguing it was being investigated as a new drug. This effectively made NMN supplements legally questionable and caused several major retailers to pull products from their shelves.
That decision was reversed in September 2025, when the FDA reconsidered its interpretation and determined that NMN is not excluded from the supplement category after all. But the whiplash left many consumers uneasy. A supplement that the government briefly said shouldn’t be sold as a supplement doesn’t inspire confidence, even after the reversal. Some users stopped during the exclusion period and never resumed.
Sleep Disruption and Timing Issues
Some NMN users report difficulty sleeping, particularly when taking it later in the day. This has a plausible biological basis. NAD+ is deeply linked to the body’s circadian clock. An enzyme called SIRT1, which depends on NAD+ to function, directly interacts with core clock genes that regulate sleep-wake cycles. Boosting NAD+ levels can activate this system, and if that activation happens in the evening, it may interfere with the signals your body uses to wind down.
A clinical trial protocol published in 2023 actually proposed testing NMN as a treatment for chronic insomnia, based on the theory that declining NAD+ contributes to age-related sleep disruption. The relationship between NAD+ and sleep is complex. For some people, NMN improves sleep quality. For others, especially those who take it in the afternoon or evening, it acts more like a stimulant. Users who experience persistent insomnia often stop rather than continue experimenting with timing and dosage.
Minimal Side Effects, but Minimal Proof Too
Ironically, one reason people continue taking NMN is that clinical trials consistently show it’s well tolerated. A safety evaluation published in Scientific Reports found no serious adverse events in healthy adults taking NMN, with no meaningful changes in liver enzymes, kidney markers, blood pressure, or body composition. A separate study measuring liver, pancreas, heart, and kidney markers after NMN administration found no significant differences from baseline at any time point measured.
But “safe” and “effective” are different questions. The same trials that confirm NMN won’t harm you also show fairly limited benefits in humans over the study periods tested. For many people who stop, the calculation is straightforward: it probably isn’t hurting me, but I can’t point to anything it’s clearly doing for me either. Combined with the cost, the cancer questions, and the product quality concerns, “probably safe but probably not doing much” becomes a reason to redirect that money elsewhere.
The Dose Plateau Problem
Users who research NMN dosing eventually encounter a ceiling. The multicenter clinical trial testing escalating doses found that clinical efficacy, measured by both NAD+ blood levels and physical performance, peaked at 600 mg daily. Taking 900 mg didn’t produce better results. This plateau frustrates users who assumed that more would mean better, and it raises a practical question: if 600 mg is the ceiling and the benefits at that dose are modest, is the supplement doing enough to justify long-term use?
Some users also worry about what happens when they stop. Because NMN raises NAD+ levels artificially, there’s a concern (not yet confirmed in human studies) that the body may downregulate its own NAD+ production in response. This creates a psychological trap where people feel locked into taking something they’re not sure is helping, simply because they’re afraid stopping might make things worse. Eventually, many decide to just stop and see what happens, and when nothing dramatic changes, they don’t go back.